Press ReleasesLatest news from MBio
MBio Diagnostics Announces Two Contracts for Sepsis Test Development
Sepsis tests will be developed in collaboration with the Cincinnati Children’s Hospital Medical Center (CCHMC) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) to address the critical need for more effective sepsis patient management in clinical and field settings
August 1, 2019 Boulder, CO — MBio Diagnostics, Inc., today announced two new contracts for sepsis test development. The first is a Phase II Small Business Innovative Research grant from the National Institutes of Health (NIH) focused on point- of-care implementation of the pediatric sepsis mortality risk algorithm developed at the Cincinnati Children’s Hospital Medical Center (CCHMC). The second is from The Henry M. Jackson Foundation, Inc. (HJF) for the Advancement of Military Medicine for development of a field-forward 10-plex immunoassay for prediction of sepsis survival in areas where healthcare access is limited.
Sepsis is a devastating cause of morbidity and mortality; estimates of U.S. incidence range from 894,000 to 3.1 million cases annually. Because of its high incidence and high cost of treatment, sepsis imposes a heavy financial burden on the health care system. MBio’s NIH-funded program is in collaboration with Dr. Hector Wong, Director of Critical Care Medicine at CCHMC, whose group has developed a laboratory-based pediatric sepsis prognostic assay.
The CCHMC-MBio test combines five blood-based biomarkers with clinical inputs to quickly stratify patients by mortality risk. Dr. Wong added
“When managing care for these gravely ill children, we need test results at the bedside in minutes – not hours later in the laboratory,” said Dr. Wong. “Phase I data on the MBio point-of-care platform showed excellent correlation with data we have been generating in the laboratory over the last several years. We are very excited about the prospect of getting this test into the ICU.”
MBio’s HJF contract is in collaboration with the Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO). The ACESO project is sponsored by the Department of Navy, Naval Medical Research Center. The ACESO group has developed a laboratory-based sepsis management algorithm based on 10 blood biomarkers. The ACESO-MBio project will establish feasibility of quantitative detection of the 10 blood biomarkers on MBio’s simple-to-use, point-of-care device.
“The ACESO sepsis tool requires measurement of multiple biomarkers in a single sample very quickly,” said HJF President and CEO Dr. Joseph Caravalho. “The MBio platform seems uniquely positioned to deliver the results we need in a format that can be effectively utilized in challenging field settings encountered in military medicine.”
MBio’s CEO Chris Myatt added,
“In addition to the devastating health impacts of sepsis, the financial burden sepsis management places on the healthcare system is enormous. By providing timely results at the point-of-care, the MBio system has the potential to both improve patient outcomes and reduce the overall costs of sepsis management. We are grateful for the confidence the NIH and HJF have shown in our system.”
About MBio Diagnostics
MBio Diagnostics provides rapid, on-the-spot testing solutions for our global commercial partners. Our portable LightDeck® platform delivers panels of lab-quality results in minutes for critical applications in health care, veterinary, and environmental industries.
About LightDeck® Technology
MBio’s patented LightDeck® technology system translates laboratory assays into on-the-spot, critical decisions in minutes. Our LightDeck® platform incorporates low-cost, multiplexed cartridges with our fluorescent readers and intuitive software, with the ability to measure more than 50 analytes in a single cartridge. Our partners use LightDeck® technology to test key analytes across many applications for competitive advantages in the areas of quantitative sensitivity, multiplexing, and speed.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a global nonprofit organization with the mission to advance military medicine. HJF’s scientific, administrative and program operations services empower investigators, clinicians, and medical researchers around the world to make discoveries in all areas of medicine. With more than 35 years of experience, HJF serves as a trusted and responsive link between the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. For more information, visit hjf.org.
MBio’s research is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R44GM125418. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Chief Marketing Officer
267-496-6391 ● Carrie.Mulherin@MBioDx.com